MIR27B (MicroRNA 27b)

Ingenuity Pathway Analysis (IPA) revealed that miR-16-5p and other miRNAs with seed AGCAGCA formed the largest interaction network in GBM, while disease enrichment analysis using Database for Annotation, Visualization, and Integrated Discovery (DAVID) confirmed that the 1000 predicted mRNA targets of DE-miRNAs in GBM were disease relevant. Collectively, these findings identify a robust panel of CSF-derived miRNAs capable of distinguishing IDH-mutant gliomas, GBM, and non-tumor states, supporting the potential of EV-miRNAs as minimally invasive biomarkers for the molecular characterization of diffuse gliomas.

This study demonstrated that MSC NVs significantly alleviated DSS-induced colitis by modulating Th17/Treg balance in the colonic lamina propria, with hsa-miR-27b-3p identified as the key mediator through PIK3CA targeting and PI3K/AKT/STAT3 pathway inhibition. These findings highlight the therapeutic potential of filtration-extrusion-prepared MSC NVs as a safe and effective nanomedicine for IBD treatment.

A multi-biomarker model combining the selected exosomal miRNAs with metabolic molecules could improve the diagnostic performance with an AUC of 0.927. Plasma exosomal miR-223-3p, miR-27a-3p, miR-27b-3p, and IBA, IVA, VA, and AA in advanced patients are closely associated with brain metastasis and have the potential to act as biomarkers for predicting brain metastasis in lung cancer patients.

HCC-derived exosomes deliver Pparα to T cells and promote CD8+ T cell exhaustion and malignant progression of HCC via the miR-27b-3p/TOX regulatory axis. The mechanisms underlying T-cell exhaustion in HCC can be utilized for the advancement of anticancer therapies.

Clinical cohorts confirmed FOS's correlation with advanced T stages and recurrence risk. These findings establish BM-based stratification as a prognostic tool and implicate the FOS-miR-27b axis as a therapeutic target, bridging metabolic heterogeneity with molecular mechanisms in PC progression. Our research offers a critical opportunity to delineate novel metabolic checkpoints that may offer therapeutic vulnerabilities for advanced prostate malignancies.

In conclusion, this study demonstrated that concurrent exposure to neonicotinoid insecticides and triazole fungicides may damage the prostate and potentially contribute to the development of prostate neoplasia. These findings emphasise the importance of further in vitro and in vivo validation to establish a definitive causal relationship and provide insight into the toxicological effects of pesticide exposure on prostate health.

In vitro, miR-27b was found to reduce metastatic potential by negatively regulating FN1 expression at the translational level. These findings suggest FN1, driven by miR-27b, as a potential driver of metastasis in HPV-negative HNSC, offering new avenues for biomarker development and targeted therapeutic strategies.

Notably, miR-34a-5p showed a connection to oligodendrocyte mitochondria, while miR-15b targeted two MR hub genes, SDHC and BCL2. Moreover, several hub proteins (HIF1A, STAT3, MAPK1, GSK3B) targeted by these miRNAs are well-known regulators of inflammatory pathways and mitochondrial homeostasis: These findings highlight the critical roles of ncRNAs in mitochondrial dysfunction and neurodegeneration, emphasizing the urgent need for experimental studies on MRmiRNAs, particularly in the context of MS and other myelinopathies.

For MDS, DAI-CCNA2 was simulated in comparison with CCNA2-Olaparib (OLA), an approved drug for breast cancer. MDS results verified DAI (the proposed drug) to be a potential candidate to combat breast cancer. Identification of druggable polyphenols using such a comprehensive in-silico approach can aid in providing a novel therapeutic strategy to combat the drawbacks associated with conventional therapies that can be further validated in an experimental setup.

Low expression of SNHG22 was more conducive to the survival of patients than high expression of SNHG22. The lncRNA SNHG22 regulated the progression of glioma by targeting miR-27b-3p, which reflected the prognostic potential of SNHG22 and provided a meaningful theoretical reference for the treatment of glioma patients.